Bizarre Patents
A Christmas stocking having illumination means associated therewith for signalling the arrival of Santa Claus.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8168188 | Antibody and utilization of the same The present invention is directed to providing an antibody having greater reactivity with amylospheroid than with amyloid β fibers, and the like. The aforementioned antibody includes an antibody having activity of inhibiting amylospheroid formation or activity of i... | 05/01/2012 |
| 8071101 | Antibody therapy for treatment of diseases associated with gluten intolerance The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or glu... | 12/06/2011 |
| 7662384 | Use of anti-α5β1 antibodies to inhibit cancer cell proliferation The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the ... | 02/16/2010 |
| 7566452 | Cancer treatment with endothelin receptor antagonists The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or... | 07/28/2009 |
| 7435412 | Chronic lymphocytic leukemia cell line The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are usefu... | 10/14/2008 |
| 7435797 | Anti-HER2 antibody variants The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains ... | 10/14/2008 |
| 7435416 | Anti-tumor antibody compositions and methods of use The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies. ... | 10/14/2008 |
| RE40535 | Anti-KC4 humanized monoclonal antibody and cells that express the antibody An anti-KC-4 humanized monoclonal antibody that comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody, wherein the light chain has 7 amino acids and the heavy chain has 12 amino acids of the framework regions substituted with ... | 10/07/2008 |
| 7429381 | Production and use of novel peptide-based agents for use with bi-specific antibodies The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antib... | 09/30/2008 |
| 7427403 | Methods for inhibiting lymphotoxin β receptor signalling This invention relates to compositions and methods comprising “lymphotoxin-β receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, a... | 09/23/2008 |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7416726 | Enhancement of antibody-mediated immune responses The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcγRIIB-mediated activity. In particular, disrupting SHIP activation by FcγRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The inven... | 08/26/2008 |
| 7399470 | Sandwich immunoassay kits for detecting ciguatoxin CTX3C A sandwich immunoassay kit for detecting ciguatoxins based on a combination of two anti-ciguatoxin CTX3C monoclonal antibodies produced by hybridomas, 3D11 (deposited at IPOD, AIST under accession number FMRM PB-8293) and 10C9 (FMRM PB-8292). In particular, one of t... | 07/15/2008 |
| 7390489 | Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody The present invention relates to a monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes, a hybridoma cell producing the monoclonal antibody, a test kit comprising the monoclonal antibody, and a method for detecting Listeria... | 06/24/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7374765 | Methods and compositions for diagnosis and treatment of iron misregulation diseases Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists. ... | 05/20/2008 |
| 7371379 | Dosages for treatment with anti-ErbB2 antibodies The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody. | 05/13/2008 |
| 7368428 | Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis Methods and compositions for restoring sensitivity to the antitumorigenic effects of antiestrogen therapy and/or cytotoxic therapy and inducing cell apoptosis are provided. Contacting tumor cells to GP88 antagonists (e.g., anti-GP88 antibodies, anti-GP88 antisense n... | 05/06/2008 |
| 7355014 | Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use A human IFN-γ inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-γ inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised ag... | 04/08/2008 |
| 7344714 | Production of motif-specific and context-independent antibodies using peptide libraries as antigens The present invention is related to a method for producing motif-specific, context-independent antibodies which are specific to at least one modified amino acid residue in the context of variable surrounding amino acid or peptide sequences. The method is particularl... | 03/18/2008 |
| 7318924 | Antibodies against cancer An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a s... | 01/15/2008 |
| 7300765 | SC6 for diagnosis of cancers The present invention relates to new uses of Solute Carrier 6 (SC6), a taurine transporter, in the diagnosis, screening, treatment and prophylaxis of hypoxia related conditions e.g. cancer. Compositions comprising the protein, such as vaccines and agents that modula... | 11/27/2007 |
| 7264807 | Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms This invention pertains to a method for treating ulcerative colitis. Specifically, the method comprises orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of an antibody which binds to a tropomyosin isoform assoc... | 09/04/2007 |
| 7238785 | RS7 antibodies This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an e... | 07/03/2007 |
| 7227002 | Human antibodies that bind human 17-A1/EpCAM tumor antigen The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP... | 06/05/2007 |
| 7211257 | Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by modulating the regeneration and tolerance factor (RTF). ... | 05/01/2007 |
| 7198787 | Method of killing target cells in harvested cell populations with one or more immuno-toxins A method for killing unwanted target cells in a cell population comprising nucleated cells harvested from peripheral blood, or CD-34+ or similar early progenitor cells selected from the above nucleated cells or from bone marrow aspirates, in which method the cell po... | 04/03/2007 |
| 7192586 | Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen Methods and compositions for treating, preventing, or diagnosing epidermal or dermal disorders, e.g., psoriasis, are disclosed. The methods and compositions of the invention use binding agents, e.g., antibodies, specific for the extracellular domain of human prostat... | 03/20/2007 |
| 7189816 | Compounds An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastroin... | 03/13/2007 |
| 7189397 | Cytotoxicity mediation of cells evidencing surface expression of CD44 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ... | 03/13/2007 |
| 7189824 | Tumor vessel endothelial cell-binding monoclonal antibodies A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing the monoclonal antibody, pharmaceutical agents comprising the monoclonal antibody, as well as pharmaceuti... | 03/13/2007 |
| 7183388 | Anti-MUC-1 single chain antibodies for tumor targeting This invention provides novel antibodies that specifically bind to the cancer antigen MUC-1. The antibodies are useful targeting moieties for specifically directing imaging agents and various therapeutic moieties to a cancer. ... | 02/27/2007 |
| 7151169 | Specific binding members for TGFβ The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGFβ | 12/19/2006 |
| 7125541 | Combined methods for tumor vasculature targeting and tumor treatment with radiotherapy The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the v... | 10/24/2006 |
| 7118741 | Transepithelial transport of molecular species There is disclosed a synthetic cross-linker protein capable of binding a molecule or macromolecular species to a transcytosis receptor for transport of the molecule or macromolecule species across a mucous membrane, said cross-linker protein comprising a first bindi... | 10/10/2006 |
| 7115577 | Colorectal neoplasia prophylaxis Development of colorectal neoplasia in a patient subject or predisposed to colorectal neoplasia is reduced by the steps of (a) determining a patient is subject or predisposed to colorectal neoplasia; and (b) enterically delivering into the gut of the person an effec... | 10/03/2006 |
| 7115716 | Tumor specific monoclonal antibodies The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also prov... | 10/03/2006 |
| 7112317 | Combined methods and compositions for tumor vasculature targeting and tumor treatment The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the v... | 09/26/2006 |
| 7097836 | Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody The present invention provides a method for enhancing the efficacy of chemotherapeutic agents for therapy of cancer and other angiogenesis-associated diseases such as rheumatoid arthritis. The method comprises the steps of administering to an individual in need of t... | 08/29/2006 |
| 7094404 | Method for treating malignancy and autoimmune disorders in humans using tac antibodies The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. 90Y-Conjugated anti-Tac or Ricin A conjugated an... | 08/22/2006 |
